Search

Your search keyword '"Montaguti, Mia Hold"' showing total 2 results
Start Over Author "Montaguti, Mia Hold"
2 results on '"Montaguti, Mia Hold"'

1. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

Author

Herrera, F., Cuervo, Guillermo, Carratalà, J., Novo, A., Manzur, A., Tilley, R., Yáñez, L., Del Pozo, J.L., Peghin, M., Araos, R., Hemmatti, P., Gomes, M.Z.R., Marin, J.I., Márquez-Gómez, I., Calik, S., Sipahi, O.R., Kanj, S.S., Montero, M., Maestro-De La Calle, G., Morales, I., Kern, W.V., Isler, B., García, E., Brunel, A.-S., Paz Morales, H., Drgona, L., Gasch, O., Tubau, Fe, Escrihuela-Vidal, Francesc, Martín-Dávila, P., Aguado, José María, Horcajada, Juan Pablo, Mikulska, M., Tebé, Cristian, Arias, Marisol Rodríguez, Aguilar-Company, Juan, Larrosa, Nieves, Cardozo, Celia, Garcia-Vidal, Carolina, Karim-Yaqub, Ibrahim, Greco, Raffaella, Montejo, M., AKOVA, MURAT, Oltolini, C., Abdala, E., Puerta-Alcalde, P., Ruiz-Camps, I., Mussetti, A., Pallarès, N., Laporte-Amargós, J., Albasanz-Puig, A., Gudiol, C., Cichero, Paola, Ayaz, Caglayan Merve, Céspedes, Roberto, López-Soria, Leire, Magnasco, Laura, Fortún, Jesús, Torres, Diego, Boté, Anna, Espasa, Mateu, Montaguti, Mia Hold, Bochud, Pierre-Yves, Manuel, Oriol, Carrasco, Salvador Tabares, López, Josefina Serrano, Bertz, Hartmut, Rieg, Siegbert, De Cueto, Marina, Rodríguez-Baño, Jesús, Lizasoain, Manuel, Sangro Del Alcázar, Paloma, Castaldo, Nadia, Bassetti, Matteo, Munita, Jose, Maschmeyer, Georg, Tonhá, João Pedro Silva, Aparecida Da Silva Machado, Amanda, Correa, Lina Clemencia, Palop, Begoña, Nazli-Zeka, Arzu, Uyan-Onal, Ayse, Jabbour, Jean-Francois, El Zein, Saeed, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, and Ege Üniversitesi

Subjects
Male, Carbapenem, Bacteremia, predictive model, 0302 clinical medicine, Risk Factors, Drug Resistance, Multiple, Bacterial, Neoplasms, Pharmacology (medical), 030212 general & internal medicine, Antibiotic prophylaxis, Cancer, 0303 health sciences, Middle Aged, Antibiotic coverage, Anti-Bacterial Agents, Infectious Diseases, Treatment Outcome, Pseudomonas aeruginosa, Female, medicine.drug, medicine.medical_specialty, Neutropenia, Antibiotic sensitivity, bloodstream infection, Microbial Sensitivity Tests, Tazobactam, Models, Biological, Epidemiology and Surveillance, 03 medical and health sciences, Internal medicine, medicine, cancer, Humans, Pseudomonas Infections, multidrug resistant, Pseudomonas aeruginosa, bacteremia, bloodstream infection, neutropenia, cancer, risk factors, predictive model, Retrospective Studies, Pharmacology, 030306 microbiology, business.industry, multidrug resistant, Retrospective cohort study, Odds ratio, Multidrug resistant, Risk factors, ROC Curve, Predictive model, Bloodstream infections, business, Bloodstream infection, Piperacillin
Abstract

We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) Pseudomonas aeruginosa in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to P. aeruginosa conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. of a total of 1,217 episodes of BSI due to P. aeruginosa, 309 episodes (25.4%) were caused by MDR strains. the rate of multidrug resistance increased significantly over the study period (P = 0.033). Predictors of MDR P. aeruginosa BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR), 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR P. aeruginosa. the application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development., ESGBIES study group; ESGICH study group; Spanish Plan Nacional de I+D+i 2013-2016; Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0001]; European Development Regional Fund A Way To Achieve Europe, Operative Program Intelligent Growth 2014-2020; Promex Stiftung fur die Forschung (Carigest SA); GileadGilead Sciences; PfizerPfizer, We thank the ESGBIES and the ESGICH study groups for supporting the study.; This study was supported by the Spanish Plan Nacional de I+D+i 2013-2016 and the Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (grant REIPI RD16/0016/0001), cofinanced by the European Development Regional Fund A Way To Achieve Europe, Operative Program Intelligent Growth 2014-2020.; A.-S.B. received a grant from Promex Stiftung fur die Forschung (via Carigest SA) and funding from Gilead to attend the ECCMID Congress (2018). O.R.S. received speaker honoraria from MSD, Astellas, Novartis, and Pfizer. S.S.K. received speaker honoraria from Pfizer, MSD, Astellas. F.H. received speaker honoraria from MSD, and Pfizer and a research and educational grant from Pfizer. the rest of the authors declare no conflicts of interest.

Published
2020

2. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study

Author

Albasanz-Puig, Adaia, Gudiol, Carlota, Parody, Rocio, Tebe, Cristian, Akova, Murat, Araos, Rafael, Bote, Anna, Brunel, Anne-Sophie, Calik, Sebnem, Drgona, Lubos, Garcia, Estefania, Hemmati, Philipp, Herrera, Fabian, Ibrahim, Karim Yaqub, Isler, Burcu, Kanj, Souha, Kern, Winfried, Maestro de la Calle, Guillermo, Manzur, Adriana, Ivan Marin, Jorge, Marquez-Gomez, Ignacio, Martin-Davila, Pilar, Mikulska, Malgorzata, Montejo, Jose Miguel, Montero, Milagros, Paz Morales, Hugo Manuel, Morales, Isabel, Novo, Andres, Oltolini, Chiara, Peghin, Maddalena, Luis del Pozo, Jose, Puerta-Alcalde, Pedro, Ruiz-Camps, Isabel, Resat Sipahi, Oguz, Tilley, Robert, Yanez, Lucrecia, Ribeiro Gomes, Marisa Zenaide, Carratala, Jordi, Cuervo, Guillermo, Escrihuela-Vidal, Francesc, Tubau, Fe, Rodriguez Arias, Marisol, Merve Ayaz, Caglayan, Munita, Jose, Gasch, Oriol, Capilla, Silvia, Bochud, Pierre-Yves, Manuel, Oriol, Torre-Cisneros, Julian, Tabares, Salvador, Serrano Lopez, Josefina, Maschmeyer, Georg, Torres, Diego, Abdala, Edson, Bittencourt, Driele Peixoto, El Zein, Saeed, Jabbour, Jean-Francois, Bertz, Hartmut, Peyerl-Hoffmann, Gabriele, Lizasoain, Manuel, Maria Aguado, Jose, Clemencia Correa, Lina, Palop, Begona, Fortun, Jesus, Magnasco, Laura, Cespedes, Roberto, Lopez-Soria, Leire, Pablo Horcajada, Juan, Montaguti, Mia Hold, de Cueto, Marina, Rodriguez-Bano, Jesus, Greco, Raffaella, Cichero, Paola, Bassetti, Matteo, Castaldo, Nadia, Sangro del Alcazar, Paloma, Cardozo, Celia, Garcia-Vidal, Carolina, Aguilar-Company, Juan, Larrosa, Nieves, Uyan-Onal, Ayse, Nazli-Zeka, Arzu, Vasconcelos de Freitas, Wania, da Silva Machado, Amanda Aparecida, IRONIC Study Grp, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, IRONIC study group, Cuervo, G., Escrihuela-Vidal, F., Arias, M.R., Ayaz, C.M., Munita, J., Gasch, O., Bochud, P.Y., Manuel, O., Torres, D., Zein, S.E., Jabbour, J.F., Bertz, H., Peyerl-Hoffmann, G., Lizasoain, M., Aguado, J.M., Palop, B., Fortún, J., Maschmeyer, G., Magnasco, L., Céspedes, R., López-Soria, L., Horcajada, J.P., Montaguti, M.H., Cueto, M., Rodríguez-Baño, J., Greco, R., Cichero, P., Bassetti, M., Castaldo, N., Del Alcázar, P.S., Cardozo, C., Garcia-Vidal, C., Aguilar-Company, J., Larrosa, N., Uyan-Onal, A., Nazli-Zeka, A., Eylul, D., Turkey, I., Clemencia Correa, L., de Freitas, W.V., da Silva Machado, A.A., Institut Català de la Salut, [Albasanz-Puig A, Gudiol C] Departament de Malalties Infeccioses, Hospital Universitari de Bellvitge, Barcelona, Spain. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat de Barcelona, Barcelona, Spain. Spanish Network for Research in Infectious Diseases (REIPI), Instituto de Salud Carlos III, Madrid, Spain. [Parody R] Departament d’hematologia, Institut Català d' Oncologia (ICO) Barcelona, Spain. Hospital Duran i Reynals, Barcelona, Spain. . Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. [Tebe C] Servei d’estadística, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Universitat Rovira i Virgili, Barcelona, Spain. [Akova M] Infectious Diseases Department, Hacettepe University School of Medicine, Ankara, Turkey. [Araos R] Infectious Diseases Department, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana, Universidad del Desarrollo, Santiago de Chile, Chile. [Ruiz-Camps I] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, and Ege Üniversitesi

Subjects
Microbiological Phenomena::Drug Resistance, Microbial [PHENOMENA AND PROCESSES], Research design, infecciones bacterianas y micosis::infecciones bacterianas y micosis::infección::sepsis::bacteriemia [ENFERMEDADES], bacteraemia, Time Factors, modelos logísticos, International Cooperation, humanos, resistencia a medicamentos, Drug Resistance, Bacteremia, Bacteria::bacterias gramnegativas::bacterias aerobias gramnegativas::bacilos y cocos aerobios gramnegativos::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMOS], bloodstream infection, multidrug-resistant, neutropenia, onco-haematological patients, pseudomonas aeruginosa, estudios multicéntricos como asunto, Bacterièmia, 0302 clinical medicine, Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa [ORGANISMS], Drug Resistance, Multiple, Bacterial, Neoplasms, Clinical endpoint, Onco-haematological patients, Multicenter Studies as Topic, Multidrug-resistant, Microorganismes - Resistència als medicaments, Otros calificadores::Otros calificadores::/inmunología [Otros calificadores], 030212 general & internal medicine, neoplasias, 0303 health sciences, Neutropènia, fenómenos microbiológicos::farmacorresistencia microbiana [FENÓMENOS Y PROCESOS], Incidence (epidemiology), bacteriemia, General Medicine, Bacterial Infections and Mycoses::Bacterial Infections and Mycoses::Infection::Sepsis::Bacteremia [DISEASES], Anti-Bacterial Agents, Malalts de càncer, Observational Studies as Topic, Research Design, Pseudomonas aeruginosa, Ceftolozane, antibacterianos, medicine.drug, medicine.medical_specialty, Tazobactam, Neutropenia, Pseudomones aeruginosa, Bloodstream infection, 03 medical and health sciences, factores de tiempo, Other subheadings::Other subheadings::/immunology [Other subheadings], Internal medicine, Pseudomonas, medicine, Humans, Pseudomonas Infections, Anti-Bacterial Agents/therapeutic use, Bacteremia/drug therapy, Bacteremia/mortality, Cephalosporins/therapeutic use, Logistic Models, Neoplasms/complications, Neutropenia/complications, Pseudomonas Infections/drug therapy, Pseudomonas aeruginosa/isolation & purification, Retrospective Studies, Tazobactam/therapeutic use, Resistència als medicaments, infecciones por Pseudomonas, cefalosporinas, 030306 microbiology, business.industry, estudios retrospectivos, enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::leucopenia::agranulocitosis::neutropenia [ENFERMEDADES], cooperación internacional, Retrospective cohort study, Cancer patients, medicine.disease, Cephalosporins, Drug resistance, Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia [DISEASES], Bacteraemia, Observational study, business, diseño de la investigación
Abstract

The IRONIC study group: Cuervo, Guillermo; Escrihuela-Vidal, Francesc; Tubau, Fe; Rodriguez Arias, Marisol; Merve Ayaz, Caglayan; Munita, Jose; Gasch, Oriol; Capilla, Silvia; Bochud, Pierre-Yves; Manuel, Oriol; Torre-Cisneros, Julian; Tabares, Salvador; Serrano Lopez, Josefina; Maschmeyer, Georg; Torres, Diego; Abdala, Edson; Bittencourt, Driele Peixoto; El Zein, Saeed; Jabbour, Jean-Francois; Bertz, Hartmut; Peyerl-Hoffmann, Gabriele; Lizasoain, Manuel; Maria Aguado, Jose; Clemencia Correa, Lina; Palop, Begona; Fortun, Jesus; Magnasco, Laura; Cespedes, Roberto; Lopez-Soria, Leire; Pablo Horcajada, Juan; Montaguti, Mia Hold; de Cueto, Marina; Rodriguez-Bano, Jesus; Greco, Raffaella; Cichero, Paola; Bassetti, Matteo; Castaldo, Nadia; Sangro del Alcazar, Paloma; Cardozo, Celia; Garcia-Vidal, Carolina; Aguilar-Company, Juan; Larrosa, Nieves; Uyan-Onal, Ayse; Nazli-Zeka, Arzu; Vasconcelos de Freitas, Wania; da Silva Machado, Amanda Aparecida, [Introduction]: Pseudomonas aeruginosa (PA) has historically been one of the major causes of severe sepsis and death among neutropenic cancer patients. There has been a recent increase of multidrug-resistant PA (MDRPA) isolates that may determine a worse prognosis, particularly in immunosuppressed patients. The aim of this study is to establish the impact of antibiotic resistance on the outcome of neutropenic onco-haematological patients with PA bacteraemia, and to identify the risk factors for MDRPA bacteraemia and mortality., [Methods and analysis]: This is a retrospective, observational, multicentre, international study. All episodes of PA bacteraemia occurring in neutropenic oncohaematological patients followed up at the participating centres from 1 January 2006 to 31 May 2018 will be retrospectively reviewed. The primary end point will be overall case-fatality rate within 30 days of onset of PA bacteraemia. The secondary end points will be to describe the following: the incidence and risk factors for multidrugresistant and extremely drug-resistant PA bacteraemia (by comparing the episodes due to susceptible PA with those produced by MDRPA), the efficacy of ceftolozane/tazobactam, the rates of persistent bacteraemia and bacteraemia relapse and the risk factors for very early (48 hours), early (7 days) and overall (30 days) case-fatality rates., [Ethics and dissemination]: The Clinical Research Ethics Committee of Bellvitge University Hospital approved the protocol of the study at the primary site. To protect personal privacy, identifying information of each patient in the electronic database will be encrypted. The processing of the patients’ personal data collected in the study will comply with the Spanish Data Protection Act of 1998 and with the European Directive on the privacy of data. All data collected, stored and processed will be anonymised. Results will be reported at conferences and in peerreviewed publications., This study was supported by Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001) and co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Programme Intelligent Growth 2014‐2020.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results